1. Immunology/Inflammation
  2. PD-1/PD-L1

PD-1/PD-L1

Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.

Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.

In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.

PD-1/PD-L1 Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-19745
    BMS-202 Inhibitor 99.37%
    BMS-202 is an inhibitor of the PD-1/PD-L1 protein/protein interaction with an IC50 of 18 nM.
  • HY-19991
    BMS-1 Inhibitor 99.61%
    BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
  • HY-101093
    PD-1-IN-1 Inhibitor 98.48%
    PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4.
  • HY-108730
    Avelumab Inhibitor >99.0%
    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
  • HY-102011
    BMS-1166 Inhibitor 99.79%
    BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM.
  • HY-101097A
    PD-1-IN-17 TFA Inhibitor
    PD-1-IN-17 TFA is a programmed cell death- 1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM.
  • HY-101097
    PD-1-IN-17 Inhibitor
    PD-1-IN-17 is a programmed cell death- 1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM.
  • HY-101093B
    PD-1-IN-20 Inhibitor
    PD-1-IN-20 is a PD-1 inhibitor.
  • HY-B0333
    Sulfamethizole Inhibitor 99.71%
    Sulfamethizole is a sulfathiazole antibacterial agent.
  • HY-B1387
    Sulfamethoxypyridazine Inhibitor 99.01%
    Sulfamethoxypyridazine is a long-acting sulfonamide antibiotic, for treatment of Dermatitis herpetiformis.
  • HY-101098
    PD-1-IN-18 Inhibitor
    PD-1-IN-18 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.